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Abstract We found that sparse and confluent C6 glioma cells
differ both in GM3 content, which increases with cell density, and
in endothelin-1 (ET-1)-induced phosphoinositide hydrolysis,
which was markedly higher in the sparse cells than in the
confluent. Also after manipulation of the cellular GM3 content
through treatment with exogenous GM3 or with drugs known to
affect GM3 metabolism, the ET-1 effect was inversely related to
GM3 cellular levels. Cell treatment with an anti-GM3 mAb
resulted in the enhancement of ET-1-induced phospholipase C
activation and restored the capacity of GM3-treated cells to
respond to ET-1. These findings suggest that the GM3 ganglio-
side represents a physiological modulator of ET-1 signaling in
glial cells. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Gangliosides are a family of sialic acid-containing glyco-
sphingolipids located almost exclusively in the outer lea£et
of the plasma membrane and particularly abundant in the
nervous system [1]. The peculiar structure and the localization
of gangliosides result in their involvement in several interac-
tion mechanisms, such as those with external stimuli, recep-
tors and transduction molecules [2^4]. In fact there is a sig-
ni¢cant body of literature that suggests that di¡erent
gangliosides, particularly GM3, are able to a¡ect the interac-
tion of di¡erent ligands with their speci¢c receptors and en-
zymes involved in protein phosphorylation/dephosphoryla-
tion, and second messenger generation [2,3]. These
properties result in cellular gangliosides contributing to the
regulation of crucial cell processes such as proliferation, dif-
ferentiation and oncogenesis [4,5].
Within the plethora of extracellular signals that regulate cell
function in the nervous system endothelin (ETs), and above
all ET-1, represent a class of molecules that plays a crucial
role in CNS functioning, acting as neurotransmitters or neu-
romodulators [6]. Besides neurons, also glial cells express ET
genes and ET receptors, that are also involved in stimulating
cell proliferation [6]. The role of ETs in glial cells is under-
scored by the evidence that these bioactive peptides are in-
volved in patho-physiological processes such as traumatic in-
jury, ischemia, and glial tumors [6]. In both astrocytes and
glioma cells ET-1 exerts its e¡ects through the signal trans-
duction pathway that involves the stimulation of phosphati-
dylinositol (PI) turnover via phospholipase C (PLC) activa-
tion [7]. Notwithstanding this evidence, little is known on the
regulatory molecules of ET-coupled signal transduction and,
in particular, on the possible role played by gangliosides in
this process, especially in glial cells.
In the present study we investigated the possible e¡ect of
gangliosides on ET-1 receptor-mediated signaling pathway
and, for this purpose, C6 glioma cells were chosen as the
experimental model. Like other glial cells, these cells exhibit
both a simpli¢ed ganglioside pattern, characterized by the
preponderance of GM3 species [8], and express ET receptors
coupled with the activation of a PI-speci¢c PLC [9^11]. The
data obtained strongly support the action, in C6 cells, of
cellular GM3 as a negative modulator of the ET-coupled sig-
nal transduction mechanism.
2. Materials and methods
2.1. Chemicals
Dulbecco’s modi¢ed Eagle’s medium (DMEM), fetal calf serum
(FCS), brefeldin A (BFA), bovine serum albumin (BSA), and Neu5Ac
were from Sigma (St. Louis, MO, USA). N-Butyldeoxynojirimycin
(NB-DNJ) was from Biomol (Plymouth Meeting, PA, USA). ET-1
was from Calbiochem (La Jolla, CA, USA). [myo-2-3H]inositol (22
Ci/mmol) was from New England Nuclear (Boston, MA, USA). The
gangliosides GM3, GM2 and GM1 were prepared and puri¢ed as
previously described [12]. The monoclonal antibody anti-GM3 DH2
(mouse IgG3) [13] was kindly provided by Prof. S.-I. Hakomori
(Paci¢c Northwest Research Institute, Seattle, WA, USA). Total
mouse IgG was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Dowex anion-exchange resin (AG1-X8, formate form, 200^
400 mesh) was purchased from Bio-Rad (Richmond, CA, USA) and
high performance thin layer chromatography (HPTLC) silica gel
plates were from Merck (Darmstadt, Germany).
2.2. Cell culture
Rat C6 glioma cells were cultured in DMEM supplemented with
10% FCS, 100 U/ml of penicillin and 100 Wg/ml streptomycin, in an
atmosphere of 5% CO2/95% humidi¢ed air. The cells were plated in
35- and 100-mm diameter dishes at 4000 and 16 000 cells/cm2 in order
to obtain sparse and con£uent cell populations respectively. The cul-
ture medium was changed 48 h after plating and the cells were grown
for another 24 h at 37‡C. BFA was added to the growth medium at
1 Wg/ml ¢nal concentration, NB-DNJ and gangliosides GM3, GM2
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and GM1 at 50WM unless otherwise stated. All treatments were done
for 24 h in the presence or absence of [myo-3H]inositol for IP deter-
mination and ganglioside analysis, respectively.
2.3. Determination of inositol phosphate (IP) formation
The phosphoinositide hydrolysis was measured as previously de-
scribed [11,14] with minor modi¢cations. Cells, grown in 35-mm cul-
ture dishes for 72 h, were labeled to equilibrium in the last 24 h with
[myo-3H]inositol (1 WCi/ml) in DMEM supplemented with 10% FCS.
After labeling, the medium was removed and the cells were washed
three times with physiological saline solution (118 mM NaCl, 4.7 mM
KCl, 1.8 mM CaCl2, 1.2 mM MgCl2, 1.2 mM KH2PO4, 11 mM
glucose and 20 mM HEPES, pH 7.4). After a 15-min preincubation
at 37‡C in the same bu¡er containing 20 mM LiCl, the cells were
stimulated with 100 nM ET-1. In most experiments the incubation
time was 15 min. At the end, after rapid aspiration of the solution
from the cells, 0.5 ml ice-cold methanol/concentrated HCl (100:1, v/v)
was added and the cells were scraped o¡ the plates and transferred to
test tubes. Chloroform (0.5 ml) and 10 mM EDTA (0.25 ml) were
added and, after vortexing, the aqueous and organic phases were
separated by centrifugation (5000Ug, 5 min, 4‡C). The aqueous
phase, containing water-soluble [3H]inositol-labeled compounds, was
then applied to a Dowex AG 1U8 (200^400 mesh, formate form)
column. After the elution of free [3H]inositol and [3H]glycerophos-
phoinositols, the total [3H]IPs (IP1, IP2 and IP3) were eluted in a
single step with 5 ml of 1 M ammonium formate/0.1 M formic acid
and then counted for radioactivity. [3H]IP levels are expressed as the
percentage of the total radioactivity associated with [3H]inositol-
labeled phospholipids, recovered in the organic phase.
When anti-GM3 mAb DH2 (IgG3) and total mouse IgG were used,
the cells were incubated with these agents at 1 Wg/ml during the pre-
incubation in the presence of lithium and before ET-1 stimulation.
2.4. Ganglioside analysis
The cells (grown on 100-mm dishes) were scraped o¡ the plates,
lyophilized and then subjected to lipid extraction [15]. The total lipid
extract was subjected to a two-phase partitioning [16], with an addi-
tional washing of the organic phase. After this washing the recovery
of cellular GM3 in the aqueous phase was found to be higher than
93%. The obtained aqueous phase, containing gangliosides, was sep-
arated by HPTLC using chloroform/methanol/0.2% CaCl2 (55:45:10,
by volume). After spraying the plates with a p-dimethylaminobenzal-
dehyde reagent [17], GM3 was quanti¢ed by densitometric analysis
(Molecular Analyst program, Bio-Rad Laboratories).
2.5. Other methods
Ganglioside-bound sialic acid was determined by the resorcinol^
HCl method [18] using Neu5Ac as the standard; cell protein were
assayed [19] using BSA as the standard. Statistical signi¢cance of
di¡erences was determined by Student’s t-test.
3. Results and discussion
Preliminary experiments were carried out to determine the
kinetic pro¢le of PI hydrolysis after ET-1 stimulation of the
C6 glioma cells. The administration of 100 nM ET-1 to C6
cells induced a signi¢cant and time-dependent increase in
[3H]IPs (Fig. 1). This increase in the PI hydrolysis products
was already evident 5 min after stimulation, increasing there-
after and reaching the highest levels (365% of unstimulated
cells) at 15 min. With continued incubation, for up to 1 h, the
[3H]IPs level declined gradually. Thus 15 min cell stimulation
with 100 nM ET-1 was used throughout the study.
In agreement with previous studies [8], the analysis of the
ganglioside composition demonstrated that the ganglioside
pattern of C6 cells is simpli¢ed and characterized by the prev-
alence (more than 95%) of GM3. The preponderance of GM3
was found in the C6 cells at both the sparse and the con£uent
stage. However, at these two stages of growth in culture, the
amount of cellular GM3 was signi¢cantly di¡erent (Table 1).
In particular the increase in cell density was paralleled by the
elevation of the cellular GM3 content, the con£uent cells con-
taining about 1.5-fold the amount of GM3 of sparse C6 cells.
These data are in agreement with previous, early ¢ndings [20^
22] demonstrating that in some cultured cells the content of
GM3 (and other glycosphingolipids) is dependent on the cell
density. Interestingly, we found that sparse and con£uent C6
cells also displayed a di¡erent response to ET-1. In fact, as
shown in Table 1, the radiolabeled IP amount accumulated in
the sparse cells was about 150% that of the con£uent cells.
The evidence that C6 cells at di¡erent stages of con£uence
di¡er both in their GM3 content and response to ET-1,
prompted us to focus our study on the possible role of
GM3 as a cellular modulator of ET-1 receptor-coupled PLC
activation. Our initial approach was to evaluate whether C6
glioma cells, at the same growth stage but with di¡erent GM3
content, respond di¡erently to ET-1. We ¢rst administered
GM3 ganglioside (in the range 2^50WM) to sparse C6 cells
for 24 h. After removal of the exogenous ganglioside the
GM3-treated cells were analyzed for both GM3 content and
ET-1 response. In the experimental conditions used the ad-
ministration of GM3 resulted in a dose-dependent increase in
cellular GM3 content (Fig. 2, upper panel). This is in agree-
ment with previous evidence demonstrating that exogenous
Fig. 1. Time course of ET-1-induced IP formation in C6 cells. Cells
were labeled to equilibrium with [myo-3H]inositol and then incu-
bated with 100 nM ET-1 for di¡erent times, up to 60 min. Total
[3H]IPs were extracted and separated as described in Section 2.
Data are expressed as the percentage of total [3H]PIs, and are the
mean values þ S.D. of three independent experiments. Basal [3H]IPs
levels were similar at all the incubation times.
Table 1
GM3 content and ET-1 response in C6 glioma cells at di¡erent den-
sity
Cell density GM3 (nmol/mg protein) IP (% of basal level)
Sparse cells 2.90 þ 0.37 365 þ 11
Con£uent cells 4.25 þ 0.53** 245 þ 15**
Sparse and con£uent cells were obtained as described in Section 2.
IP accumulation was measured after 15 min stimulation with 100
nM ET-1. Data are the mean þ S.D. of three independent experi-
ments in duplicate. **P6 0.001 vs. sparse cells.
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gangliosides can be taken up by cells and inserted into the
plasma membrane, like endogenous compounds [23]. In GM3-
treated cells ET-1-induced PLC activation, evaluated as PI
hydrolysis, was lower than in untreated cells (lower panel,
Fig. 2). The inhibitory e¡ect was directly related to the
amount of cellular GM3 and, at the highest dose, the ET-1-
induced IP formation was decreased by about 50%. This e¡ect
appeared to be speci¢c, since in the same experimental con-
ditions two other monosialogangliosides, GM2 and GM1 (up
to 50WM), did not produce any relevant e¡ect on ET-1-stimu-
lated IP formation (93 þ 8.6 and 97 þ 9.0% of control, for
GM2 and GM1, respectively).
In further experiments, ET-1 was incubated with the GM3
ganglioside (for 15 min at 37‡C) prior to its administration to
cells. The analysis of IP formation indicated that the preincu-
bation of ET-1 with GM3 (up to 50WM) had no e¡ect on the
PLC activation by the stimulus (96 þ 10.5% of control). Thus
it appears that the e¡ect of GM3 on ET-1 response does not
occur through the direct interaction of the ganglioside with
this peptide. On the basis of the present data and previous
evidence supporting the implication of gangliosides in recep-
tor function [2^4], it can be speculated that GM3 may act
through the modulation of ET receptors.
To further support that cellular levels of GM3 a¡ect ET-1-
induced PLC activation, the endogenous content of GM3 was
also modi¢ed by incubating the cells with drugs known to
a¡ect ganglioside metabolism. We administered either BFA,
an inhibitor of the anterograde vesicular transport between
Golgi compartments [24], or NB-DNJ, an inhibitor of gluco-
sylceramide synthase [25]. As shown in Fig. 3 (left panel),
both agents a¡ected the cellular content of GM3 markedly,
although in opposite directions: BFA caused a signi¢cant in-
crease and NB-DNJ a marked decrease in cellular GM3.
These data support previous studies [26^28] and demonstrate
that in C6 cells GM3 metabolism, is perturbed by these drugs.
Moreover, also in these experimental conditions the ET-1 ef-
fect on PI hydrolysis is inversely related to the GM3 cellular
levels (Fig. 3, right panel). In fact, compared to untreated
cells, the GM3 content in the BFA-treated cells increased by
Fig. 2. E¡ect of exogenous GM3 on cellular GM3 content and ET-
1-induced IP formation. Upper panel: Cells were incubated in the
absence or presence of GM3 ganglioside at di¡erent concentrations.
After 24 h, cells were subjected to ganglioside extraction and GM3
quanti¢cation as described in Section 2. Lower panel: Cells were in-
cubated with [myo-3H]inositol in the absence or presence of GM3
ganglioside at di¡erent concentrations. After 24 h, ET-1 (100 nM)
was added for 15 min and accumulation of total [3H]IPs deter-
mined. Data are expressed as the percentage of control (cells incu-
bated in the absence of GM3) and are the mean values þ S.D. of at
least three separate experiments. *P6 0.05; **P6 0.01.
Fig. 3. E¡ect of di¡erent treatments on GM3 content and ET-1-in-
duced IP formation. Cells were incubated for 24 h with [myo-
3H]inositol in the absence (A) or presence of 1 Wg/ml BFA (B) or
50 WM NB-DNJ (C). After stimulation with 100 nM ET-1 for 15
min, GM3 content (left panel) and total [3H]IP levels (right panel)
were measured. For each treatment the production of [3H]IPs ob-
served in the presence of ET-1 was calculated by subtraction of the
corresponding basal level without ET-1 treatment (1.39 þ 0.21,
0.88 þ 0.18 and 1.47 þ 0.25 for A, B and C, respectively) and ex-
pressed as the percentage of the response observed in ET-1-stimu-
lated control cells (A). Each point is the mean þ S.D. of three inde-
pendent experiments. **P6 0.01 vs. A.
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40%, and IP formation induced by ET-1 was reduced to 50%.
Conversely, in the NB-DNJ-treated cells there was a reduction
in the GM3 levels (by about 60%) and a higher response to
ET-1-stimulated IP formation (40% increase).
To con¢rm that cellular GM3 represents a modulator of
ET-1 response in C6 glioma cells, cells carrying di¡erent
amounts of GM3 were exposed to a speci¢c anti-GM3 mAb
before ET-1 stimulation. The treatment of sparse C6 cells with
an anti-GM3 mAb (IgG3), but not with IgG, resulted in the
enhancement of ET-1-induced PI hydrolysis (3GM3, Fig. 4).
Moreover, mAb treatment of ‘GM3-loaded’ cells resulted in
an increase in ET-1 response and appeared to restore the
capacity of these cells, impaired after GM3 treatment, to re-
spond to ET-1 (+GM3, Fig. 4).
The data presented here provide evidence that the response
of C6 cells to ET-1 is inversely related to the cellular amount
of GM3, and suggest that the ET-induced signaling activity in
glial cells may depend on the amount of this ‘modulatory’
ganglioside present in the cells. Thus, the regulation of
GM3 content may represent an e¡ective mechanism to control
ET-1 signaling and functional e¡ects in glial cells. To the best
of our knowledge our observations document the ¢rst evi-
dence that the GM3 ganglioside is able to modulate the ET-
1-mediated signaling pathway in cells, and provide a prompt
starting point for future studies on the mechanism underlying
this e¡ect.
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Fig. 4. E¡ect of anti-GM3 mAb on ET-1-induced PI turnover. C6
cells were incubated with [myo-3H]inositol in the absence (3GM3)
or presence (+GM3) of 10 WM GM3. After 24 h, cells were stimu-
lated with ET-1 prior to (control) or after treatment (1 Wg/ml,
15 min) with anti-GM3 mAb DH2 (mouse IgG3) or total mouse
IgG. Data are the mean þ S.D. of three independent experiments.
**P6 0.01.
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